https://kommunikasjon.ntb.no/pressemelding/18880183/idorsia-reports-strong-q1-2026-performance-with-74percent-quviviq-sales-growth-year-on-year?publisherId=4954260&lang=en
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year |...
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on...
sales growthreportsstrongperformancequviviq
https://www.htsyndication.com/japan-government-news/article/clinical-trial%3A-use-result-survey-to-evaluate-the-safety-and-outcome-of-quviviq-use-in-patients-with-insomnia--japan-/555740775
Clinical Trial: Use-result survey to evaluate the safety and outcome of QUVIVIQ use in patients...
clinical trialthe safetyuseresultsurvey
https://www.pharmanow.live/latest-news/nxera-quviviq-taiwan
QUVIVIQ Taiwan Approval Nxera Pharma
Nxera Pharma gains Taiwan approval for QUVIVIQ insomnia drug through partner Holling Bio-Pharma, with launch planned in 2026.
quviviqtaiwanapprovalpharma